HDLBP and metabolic dysfunction-associated steatotic liver disease: Expression of vigilin also correlated with lipid accumulation in patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) as well as livers of insulin-resistant obese mice.